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Anti-D monoclonal antibodies from 
23 human and rodent cell lines 
display diverse igG fc-glycosylation 
profiles that determine their clinical 
efficacy
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Agnes Hipgrave ederveen  3, Kathryn L. Armour4, natalia i. olovnikova5,  
Gestur Vidarsson  6*, Rick Kapur  6, Pauline M. Rudd2 & Manfred Wuhrer  3
Anti-D immunoglobulin (Anti-D Ig) prophylaxis prevents haemolytic disease of the fetus and newborn. 
Monoclonal IgG anti-Ds (mAb-Ds) would enable unlimited supplies but have differed in efficacy in 
fcγRIIIa-mediated ADCC assays and clinical trials. Structural variations of the oligosaccharide chains  
of mAb-Ds are hypothesised to be responsible. Quantitative data on 12 Fc-glycosylation features of  
23 mAb-Ds (12 clones, 5 produced from multiple cell lines) and one blood donor-derived anti-D Ig  
were obtained by HPLC and mass spectrometry using 3 methods. Glycosylation of mAb-Ds from 
human B-lymphoblastoid cell lines (B) was similar to anti-D Ig although fucosylation varied, affecting 
ADcc activity. In vivo, two B mAb-Ds with 77–81% fucosylation cleared red cells and prevented 
D-immunisation but less effectively than anti-D Ig. High fucosylation (>89%) of mouse-human 
heterohybridoma (HH) and Chinese hamster ovary (CHO) mAb-Ds blocked ADCC and clearance. Rat 
YB2/0 mAb-Ds with <50% fucosylation mediated more efficient ADCC and clearance than anti-D Ig. 
Galactosylation of B mAb-Ds was 57–83% but 15–58% for rodent mAb-Ds. HH mAb-Ds had non-human 
sugars. These data reveal high galactosylation like anti-D Ig (>60%) together with lower fucosylation 
(<60%) as safe features of mAb-Ds for mediating rapid red cell clearance at low doses, to enable 
effective, inexpensive prophylaxis.
Anti-D immunoglobulin (anti-D Ig, RhIG) is a very safe and effective prophylactic therapy to prevent haemolytic 
disease of the fetus and newborn (HDFN). After its introduction 50 years ago, deaths are now rare, approximately 
0.02 per thousand births, a reduction of about 98% since 1950 when mortality from HDFN was about 10% of 
perinatal deaths1.
However, in low- or middle-income countries HDFN still affects thousands of babies annually2. Worldwide 
estimates for 2010 were 141,000 fetal and neonatal deaths and 27,000 cases of kernicterus caused by bilirubin 
toxicity leading to a high risk of lifelong neurological dysfunction3. Many countries have insufficient, sporadic 
or no anti-D prophylaxis due to its unavailability, high cost4,5 or insufficient public healthcare organisation or 
resources2.
Anti-D Ig preparations consist of IgG fractionated from pooled plasma of hyperimmunised D-negative 
donors. These IgG preparations have multiple anti-D specificities and affinities. Relatively low doses of this 
poly-clonal anti-D (1006–3001 µg anti-D) are administered antenatally and/or postnatally to susceptible women, 
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which are D-negative with a D-positive fetus or baby. Fetal blood may leak into maternal blood by fetomaternal 
haemorrhage (FMH) through the placenta, occasionally during pregnancy but more often after parturition7,8 with 
fetal bleeds then usually of greater volume but rarely exceeding 5 mL. FMH is the cause of maternal alloimmuni-
sation9. Unique immunologic changes in pregnant and postpartum women induced by placental syncytiotroph-
oblast microparticles10,11 and pregnancy hormones12 ensure they make strong protective antibody responses 
to foreign antigens which include, unfortunately, responses to allogeneic blood cells13. Prophylactic anti-D 
accelerates the clearance of fetal D-positive red blood cells (RBC) from the maternal circulation14, preventing 
D-immunisation which may otherwise result in HDFN. Fetal RBC with bound anti-D are removed by the spleen15 
via macrophage IgG Fc receptor (FcγR)IIIa recognition of cell-bound anti-D16,17 which triggers phago-cytosis 
and non-inflammatory intracellular destruction18. Consequently, FcγRIIIa-mediated antibody-dependent 
cellular-cytotoxicity (ADCC) assays are a good predictor of red cell clearance by IgG anti-D19.
Anti-D monoclonal antibodies (mAb-Ds) would be safe, inexpensive, standardised products potentially capa-
ble of replacing anti-D Ig. Several groups have made mAb-Ds and tested them in relevant biological assays in vitro 
and in human studies of RBC clearance and prevention of D-immunisation. Surprisingly, mAb-Ds have shown 
great variability in these studies but none have yet had equivalent activity to anti-D Ig19. It was hypothesised that 
this may be due to differences in their glycosylation19,20, i.e. the composition and linkage of sugars in the oligo-
saccharide chains attached to the Fc portion of IgG21. Human IgG has a highly conserved branched glycan chain 
covalently attached to Asn297 of each Cγ2 domain (Fig. 1a). This glycan contains variable amounts of fucose, 
galactose, sialic acid, and bisecting N-acetylglucosamine (GlcNAc). Remarkably, we have found that alloimmune 
IgG1 responses against platelets and RBC antigens, including anti-D, are characterised by low fucosylation and 
increased galactosylation in most sera22–24 as well as in the anti-D component of anti-D Ig preparations25.
For this study, extensive glycosylation analyses of an anti-D Ig preparation and 23 mAb-Ds produced from 
cell lines of four species (human, mouse, hamster and rat) were performed independently by two research groups. 
The mAb-Ds comprised 12 unique clones; 5 of these clones produced anti-D from 2–4 cell lines. Fourteen of these 
mAb-Ds had been previously tested in 10 clinical studies. Retrospective data analysis of clearance of D-positive 
RBC by all 14 mAb-Ds and of prevention of D-immunisation by 6 of them is presented here. Glycosylation of 
IgG1 and IgG3 anti-Ds was determined by high-performance liquid chromatography (HPLC) analysis of fluores-
cently labelled N-glycans, before and after exoglycosidase digestion. In a second approach, N-glycans from total 
IgG1 anti-D were analysed by mass spectrometry (MS) after ethyl esterification of sialic acids. In a third approach, 
MS was also used to analyse IgG1 anti-D Fc-glycopeptides. ADCC assays were performed and glycan structural 
data were linked to ADCC activity. The data imply that cell line-dependent variations in glycosylation between 
mAb-Ds had a major influence on biological activity.
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Figure 1. Glycosylation of anti-D IgG-Fc. (a) Cartoon of the branched oligosaccharide chain covalently 
attached to Asn297 of each Fc in the Cγ2 domain of IgG. The sugar linkages are shown. Dotted lines indicate 
the structures that may or may not be present on different glycans. (b) Summary of glycosylation of anti-Ds. Bar 
chart showing the average glycosylation of IgG1 mAb-Ds produced from human B, mouse HH + NS0, hamster 
CHO and rat YB2/0 cell lines, compared to Rhophylac anti-D. The percentage of glycans with fucose, galactose, 
agalactose (G0), monogalactose (G1), digalactose (G2), sialic acid and bisecting GlcNAc of the total samples of 
each cell line group is illustrated.
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Results
Glycosylation varied markedly among the anti-Ds. Results from the three analytical methods deter-
mining 12 glycosylation features were similar (Tables 1–3) and concurred with earlier data from small-scale 
studies (Supplementary Table S1). Glycosylation of intravenous immunoglobulin (IVIG) was similar to other 
products26 and that of the IgG anti-D purified from Rhophylac 300 anti-D Ig (Rhophylac) agreed with an earlier 
report25. Glycosylation profiles of the mAb-Ds depended on the producer cell lines. The data is summarised in 
Fig. 1b.
Fucosylation. Fucosylation was high in IVIG (91%), Rhophylac (80%), and mAb-Ds from most human B 
lymphoblastoid cell lines (B) (67–95%), mouse NS0 and heterohybridoma (HH) cell lines (90–97%) as well as 
Chinese hamster ovary (CHO) cell lines (74–93%). In contrast, mAb-Ds produced from rat YB2/0 cell lines had 
much lower fucosylation (23–46%) (Table 1).
Galactosylation. The number of galactose residues on the branched oligosaccharide varied greatly. 
Galactosylation of Rhophylac (84%), most B mAb-Ds (mean 71%) and IVIG (61%) was markedly higher than 
for rodent cell mAb-Ds (mean 35%). The percentages of G0 (agalactosyl IgG), G1 (monogalactosyl IgG) and G2 
(digalactosyl IgG) were calculated for each method. Mean G2 values were over 3 times higher for human (72% 
Rhophylac, mean 52% B mAb-Ds) than for rodent cell (mean 16%) anti-Ds. G1 values for Rhophylac were slightly 
lower than for IVIG and most mAb-Ds. Strikingly, nearly half the Fc-glycans of rodent cell mAb-Ds had no galac-
tose (mean 43% G0), contrasting greatly with very low levels of G0 in Rhophylac (3.2%) and IgG1 B mAb-Ds 
(mean 4.5%) (Table 2).
Sialylation. Sialic acid is linked to galactose on IgG Fc oligosaccharides. Sialylation was approximately one 
third that of galactosylation for IVIG and Rhophylac and was relatively higher for B and HH mAb-Ds but lower 
for NS0, CHO and YB2/0 mAb-Ds (half had <10% sialylation) (Fig. 1b). IVIG, Rhophylac, B mAb-Ds and two 
YB2/0 mAb-Ds expressed only N-acetylneuraminic acid (NeuAc) while NS0 and HH cell mAb-Ds had only 
N-glycolylneuraminic acid (NeuGc) and G12-yb2/0 had both types of sialic acids. The linkage of sialic acid 
to galactose was predominantly α2,6 in IVIG, Rhophylac, B, NS0, HH and YB2/0 mAb-Ds but only α2,3 was 
detected in CHO mAb-Ds (Table 3).
Bisection. Compared to Rhophylac and other prophylactic anti-Ds25, levels of bisecting N-acetylglucosamine 
(GlcNAc) were much higher for all B mAb-Ds but lower for all rodent cell mAb-Ds, in some cases undetectable. 
G7-b and G12-yb2/0 had values closest to Rhophylac (Table 1).
Alpha galactose. Low levels of an additional galactose, Galα1–3Gal (α-Gal), were detected by 
fluorescently-labeled glycans and ethyl esterification on NS0 and HH mAb-Ds and on some human B mAb-Ds 
by ethyl esterification only (Table 1).
Antibody Cell line IgG sub- class
% Lysis in ADCC 
at 2500 ng/mL
% Fucosylation % Bisecting GlcNAc % α-Galactose
Flu Eth GP Flu Eth GP Flu Eth
IVIG
Rhophylac
1>2>3>4
1 88.2
86.8
79.8
95.7
82.1
91.6
78.0
15.6
11.0
18.4
12.0
14.2
13.2
0.0
0.0
0.0
0.0
BRAD3lab
BRAD3clin
mBRAD3
BRAD5lab
BRAD5clin
mBRAD5
G7
G12
G108
AB5
JAC10
B
B
B
B
B
B
B
B
B
B
B
3
3
3
1
1
1
1
1
1
1
1
6.5
25.7
95.9
55.1
10.9
8.8
87.7
77.0
78.9
67.8
81.2
87.3
92.5
91.6
68.9
94.0
98.9
99.5
90.2
96.6
98.5
63.9
87.2
94.9
93.9
86.8
96.3
95.3
65.6
62.0
63.9
48.8
65.8
35.5
13.3
27.0
53.9
46.8
12.8
34.2
23.2
58.7
25.2
53.9
42.9
15.0
34.8
22.9
54.6
23.6
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
1.1
2.3
0.0
0.0
0.5
1.5
2.3
Fog1
Fog1
G7
G12
AD1
NS0
HH
HH
HH
HH
1
1
1
1
1
5.4
8.4
47.8
28.5
100.0
83.6
86.0
96.8
99.2
100.0
92.4
93.0
97.9
92.3
95.9
90.2
90.5
96.6
2.3
0.0
2.5
2.6
1.1
0.0
2.4
2.3
0.4
4.5
2.5
3.6
3.6
1.5
4.4
1.0
3.5
0.6
5.3
0.0
3.5
0.4
3.2
MonoRho
rBRAD3
rBRAD5
CHO
CHO
CHO
1
3
1
28.0
17.3
32.0
92.3
73.6
90.9
92.7 0.0
0.0
0.0
2.5 0.0
0.0
0.0
Fog1
G12
R297
Fog1Δnab
YB2/0
YB2/0
YB2/0
YB2/0
1
1
1
1 null
107.3
111.1
17.5
20.3
24.2
23.0
31.6
27.2
32.9
35.4
45.6
0.0
7.7
1.0
9.4
0.0
2.7
12.2
4.5
1.5
0.0
0.0
0.0
0.0
0.0
Table 1. Analysis of total fucosylation, bisecting N-acetylglucosamine and alpha-galactose of Fc-glycans from 
IVIG, Rhophylac anti-D and mAb-Ds. Glycosylation analysis methods used were Flu (NP-HPLC analysis of 
fluorescently labelled, released N-glycans), Eth (analysis of released N-glycans by MALDI-TOF-MS after ethyl 
esterification) and GP (analysis of IgG Fc-glycopeptides by LC-MS).
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Culture methods affected glycosylation. Galactosylation was higher (77%) and fucosylation lower 
(67%) in BRAD5lab-b derived from low cell density flask culture than in the same mAb-D produced from high 
cell density hollow fibre bioreactors, BRAD5clin-b and mBRAD5-b. These had 64% and 60% galactosylation and 
81% and 90% fucosylation, respectively.
Functional activity of mAb-Ds in ADCC assays was inversely related to fucosylation. The 
anti-Ds varied greatly in sensitive natural killer (NK) cell FcγRIIIa-dependent ADCC activity. Four anti-Ds, 
namely Rhophylac, BRAD5lab-b, Fog1-yb2/0 and G12-yb2/0 exhibited sigmoidal dose-response curves and 
mediated high potency at relatively low concentrations (<100 ng/ml). All other mAb-Ds tested elicited less 
activity even at saturating concentrations. At 250 ng/ml, BRAD5lab-b had 66% and 85% greater efficacy than 
mBRAD5-b and rBRAD5-cho, respectively, while Fog1-yb2/0 and G12-yb2/0 were 95–99% more efficient than 
their B, NS0 and HH forms in ADCC assays (Fig. 2a).
Comparison of activity with fucosylation of IgG1 anti-Ds revealed a strong negative correlation with a striking 
reduction in activity when fucosylation was >80% (Fig. 2b, top panels). At 25 ng/ml, which is the mean maximum 
physiological concentration after injection of anti-D Ig27, only four anti-Ds (Fog1-yb2/0, G12-yb2/0, BRAD5lab-b 
as well as Rhophylac) were active (Fig. 2b, top left panel). At 0.75–2.5 ng/ml (approximate range of detectable 
anti-D 10 weeks after injection27) only these three mAb-Ds were active (Fig. 2a). There was no significant relation-
ship between ADCC activity and sialylation, galactosylation or bisecting GlcNAc of the anti-Ds at either 25 ng/ml 
or 750 ng/ml (Fig. 2b, lower panels). However, mBRAD5-b had equal fucosylation as G7-hh (89.5%) but higher 
ADCC (Fig. 2a) and more galactosylation (60% versus 42%) and bisecting GlcNAc (42% versus 2.8%), thus these 
sugars may have led to enhanced mBRAD5-b interactions with FcγRIIIa. The IgG3 mAb-Ds, mBRAD3-b and 
rBRAD3-cho, had lower ADCC activity than equivalent forms of BRAD5 (Fig. 2a) despite lower fucosylation.
Efficacy of mAb-Ds in human studies was affected by glycosylation. In autologous studies, 
clearance of D-positive RBC was more rapid with YB2/0 mAb-Ds (Fog128 and R29729) than anti-D Ig, fast with 
BRAD3clin-b30, slower with BRAD3 + BRAD5 (B and CHO)31 and very slow with Fog1-hh30. Clearance by 
Fog1-hh30 and Fog1-yb2/028 was markedly dissimilar despite identical amino acid sequence, which coincided 
with much lower fucosylation of Fog1-yb2/0. Unexpectedly, Fog1Δnab-yb2/0 (lacking FcγR interactions32) also 
cleared RBC28. Fucosylation of 1:3 blends of BRAD3 + BRAD5 (B and CHO) was identical (87%) but clearance 
was slightly greater with mBRAD3-b + mBRAD5-b31 having increased galactosylation, sialylation and bisection 
as compared to the CHO-cell produced variants of these antibodies (Table 4).
Using D-negative subjects, RBC clearance was slightly less effective with BRAD3clin-b and BRAD5clin-b than 
anti-D Ig33–35, regardless of the order of injection of anti-D and RBC - anti-D first33,34 or RBC first35. However, for 
HH36,37 and CHO38 mAb-Ds injected after RBC, clearance was slow and variable although for two subjects given 
anti-D (G12-hh) before RBC37, clearance was rapid (Table 5).
In the following six months, immune IgG anti-D was detected 4–24 weeks after RBC injection in 0.8% (1 
of 119) subjects given B mAb-Ds33–35, 62% receiving HH mAb-Ds36,37, 0% injected with MonoRho-cho38 and 
0%33,36–38 administered anti-D Ig (Table 5). Unexpectedly, IgM anti-D was also detected in 77% of the immunised 
Antibody Cell line IgG sub- class
% Galactosylation % G0 % G1 % G2
Flu Eth GP Flu Eth GP Flu Eth GP Flu Eth GP
IVIG
Rhophylac
1>2>3>4
1
58.8
82.3
62.1
85.6
61.1
84.4
21.2
4.6
17.3
1.7
18.4
3.3
46.9
26.2
41.1
24.2
40.8
24.4
35.4
69.2
41.6
73.4
40.7
72.2
BRAD3lab
BRAD3clin
mBRAD3
BRAD5lab
BRAD5clin
mBRAD5
G7
G12
G108
AB5
JAC10
B
B
B
B
B
B
B
B
B
B
B
3
3
3
1
1
1
1
1
1
1
1
68.6
60.7
56.8
78.5
64.0
53.5
82.6
84.2
73.7
59.9
82.7
83.4
73.3
70.8
83.8
77.8
66.4
82.6
83.8
74.5
72.5
84.9
11.4
16.2
17.8
0.0
12.1
14.3
2.2
1.1
2.7
5.0
1.5
0.8
3.9
3.5
0.0
0.0
6.4
2.8
1.3
5.5
5.2
3.0
35.0
38.8
44.8
42.9
41.7
45.7
30.3
29.5
41.9
55.5
30.5
31.7
41.4
46.8
23.8
39.4
45.4
28.7
29.4
39.7
44.3
23.8
51.0
41.3
34.4
57.1
43.1
30.6
67.5
69.4
52.8
32.1
67.4
67.5
52.6
47.4
71.8
58.1
43.8
68.3
69.1
54.7
50.3
73.0
Fog1
Fog1
G7
G12
AD1
NS0
HH
HH
HH
HH
1
1
1
1
1
40.3
27.3
41.2
20.2
42.9
20.9
39.8
22.0
38.5
45.4
24.3
44.7
28.5
37.3
38.8
59.8
37.2
65.5
27.3
63.3
29.7
52.1
32.6
34.1
59.3
33.1
55.3
40.7
41.8
26.0
43.1
28.7
46.2
31.6
45.1
29.4
37.6
39.8
31.9
43.9
30.4
43.1
19.4
14.3
19.7
5.9
19.8
5.2
17.3
7.3
19.7
25.5
8.4
22.8
13.3
15.8
MonoRho
rBRAD3
rBRAD5
CHO
CHO
CHO
1
3
1
26.5
32.6
25.9
32.7 54.4
49.0
55.6
46.7 38.3
32.7
37.0
38.8 7.3
16.2
7.4
13.3
Fog1
G12
R297
Fog1Δnab
YB2/0
YB2/0
YB2/0
YB2/0
1
1
1
1 null
10.1
54.2
16.2
56.7
44.3
19.7
61.5
45.9
45.7
81.0
20.2
71.5
16.2
27.6
68.5
17.0
29.7
30.6
17.8
51.2
24.7
54.9
56.0
23.2
42.4
48.5
47.4
1.2
28.6
3.8
29.3
16.3
8.1
40.3
21.6
22.0
Table 2. Analysis of total galactosylation and agalactosyl (G0), monogalactosyl (G1) and digalactosyl (G2) of 
Fc-glycans from IVIG, Rhophylac anti-D and mAb-Ds. Glycosylation analysis methods used were Flu (NP-
HPLC analysis of fluorescently labelled, released N-glycans), Eth (analysis of released N-glycans by MALDI-
TOF-MS after ethyl esterification) and GP (analysis of IgG Fc-glycopeptides by LC-MS).
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subjects receiving G7-hh and G12-hh37. Assessing the efficacy of MonoRho-cho was hindered by “rescue proph-
ylaxis” (anti-D Ig) given to 7 subjects with slow RBC clearance38. After protracted studies of BRAD3clin-b and 
BRAD5clin-b which included two further RBC immunisations at 6 and 9 months, 93% (26 of 28) of the respond-
ers who developed anti-D were shown to have been protected from becoming D-immunised to the initial RBC 
injection by these B mAb-Ds33–35 (Table 5).
Discussion
Fc N-glycans extend from Asn297 in the N-terminal lower hinge regions of IgG into the Cγ2 inter-domain space, 
forming weak interactions with the protein39–41. Both the Cγ2 domains and the glycans are to some extent mobile 
and asymmetric40,41. FcγRIIIa binds to both lower hinge regions42. Glycan composition may affect the N-terminal 
conformation or the relative orientation or mobility of Cγ2 domains, modifying affinity for FcγRs41, although 
the precise mechanisms remain undefined43. Glycosylation of Fab (antigen-binding) regions of anti-D is unlikely 
because the integral membrane RhD proteins are surrounded by negatively charged glycoproteins in the RBC 
membrane glycocalyx, constricting access to the antigen44. In support of this, we recently found a strong selection 
against the formation of Fab-glycans during hypermutation in anti-D45.
Anti-D represents an ideal IgG for structure/function investigation and is unique because mAb-Ds from six 
types of cell lines could be compared with anti-D Ig synthesised by plasma cells for both in vitro functional activ-
ity and in vivo clinical data. The glycosylation of anti-Ds was heterogenous, defined by the producer cells, and 
influenced their biological and clinical activities.
The contribution of individual sugars to functional activity of IgG is becoming increasingly clear and may 
prove highly relevant for mAb-Ds.
Fucose (proximal to Asn297) was the first glycan variant found to affect the activity of human IgG1, inhibit-
ing FcγRIIIa-mediated ADCC46 and phagocytosis22. It causes steric inhibition of the Fc-FcγRIIIa interaction47. 
Afucosylated IgG has high affinity for FcγRIIIa22,47 displacing plasma IgG and enabling ADCC at low concen-
trations48. Many alloantibodies, but not all, have considerably less fucose than total IgG122–25,49. Fucosylation of 
anti-D in 11 prophylactic preparations was 56%-91%, while for Rhophylac this was 81%25.
The low fucosylation (<35%) of YB2/0 mAb-Ds enabled them to be highly active (effective ADCC and fast 
red cell clearance) but fucosylation was too high in most of the B, HH and CHO mAb-Ds for high affinity ADCC 
responses and accelerated red cell clearance. BRAD5lab-b was effective but when produced for clinical use fuco-
sylation was elevated and this came with a lower efficacy. Surprisingly, most B mAb-Ds (including AB5 and 
JAC10) have minimal ADCC20,50 perhaps because EBV immortalises immature circulating B cells synthesising 
highly fucosylated IgG whereas plasma cells secreting low fucosylated protective antibodies lack EBV receptors51. 
The high fucosylation of these B mAb-Ds is likely to explain their low ADCC.
Galactosylation of IgG has been found to be regulated by estrogens52, increased during pregnancy53 and 
associated with pregnancy-induced remission of rheumatoid arthritis54. Agalactosylation levels of IgG have 
been reported to be two-fold higher in patients with rheumatoid arthritis than controls55 and associated with 
Antibody
Cell 
line IgG sub- class
% Sialylation
% 
N-Acetyl
% 
N-Glycolyl Linkage % α2,3 % α2,6
Flu Eth GP Eth Eth Flu Eth Flu Eth Flu Eth
IVIG
Rhophylac
1>2>3>4
1
19.0
27.2
23.3
30.7
19.2
32.9
23.3
30.7
0.0
0.0
α2-6
α2-6 α2-3,6
0.0
0.0
0.0
0.7
19.0
27.2
23.3
30.0
BRAD3lab
BRAD3clin
mBRAD3
BRAD5lab
BRAD5clin
mBRAD5
G7
G12
G108
AB5
JAC10
B
B
B
B
B
B
B
B
B
B
B
3
3
3
1
1
1
1
1
1
1
1
28.6
32.4
27.5
23.5
33.7
18.7
35.3
34.6
27.9
24.2
35.9
35.1
32.8
27.9
45.6
32.0
29.3
38.9
39.8
34.9
30.5
45.5
27.9
24.2
35.9
35.1
32.8
27.9
45.6
0.0
0.0
0.0
0.0
0.0
0.0
0.0
α2-3,6
α2-3,6
α2-3,6
α2-3,6
α2-3,6
α2-3,6
α2-3,6
α2-3,6
α2-3,6
α2-3,6
α2-3,6
α2-6
α2-3,6
α2-3,6
α2-6
12.0
10.1
14.2
4.2
10.3
10.2
0.7
0.6
0.6
0.0
2.3
1.4
0.0
16.6
17.4
19.5
14.5
25.1
24.4
27.2
23.6
35.3
35.1
30.5
26.5
45.6
Fog1
Fog1
G7
G12
AD1
NS0
HH
HH
HH
HH
1
1
1
1
1
5.8
11.7
22.8
10.2
7.5
6.6
29.1
15.8
30.2
9.8
10.7
25.7
18.5
19.3
0.0
0.0
0.0
0.0
0.0
7.5
6.6
29.1
15.8
30.2
α2-3,6
α2-3,6
α2-3,6
α2-6
α2-3,6
α2-6
α2-3,6
α2-3,6
α2-3,6
0.9
2.5
2.8
0.0
1.4
0.0
1.7
1.7
1.6
4.9
9.3
20.0
10.2
6.2
6.6
27.4
13.9
28.6
MonoRho
rBRAD3
rBRAD5
CHO
CHO
CHO
1
3
1
0.0
5.2
3.5
5.9 0.0
α2-3
α2-3
0.0
5.2
3.5
0.0
0.0
0.0
Fog1
G12
R297
Fog1Δnab
YB2/0
YB2/0
YB2/0
YB2/0
1
1
1
1 null
0.0
14.3
1.7
17.0
6.3
4.4
22.3
9.8
14.6
1.7
10.4
6.3
0.0
6.7
0.0
0.0
α2-3,6
α2-6
α2-3,6
α2-6
0.0
3.7
0.0
1.1
0.0
0.0
10.6
1.7
15.9
6.3
Table 3. Analysis of total sialylation, sialic acid types and linkages of Fc-glycans from IVIG, Rhophylac anti-D 
and mAb-Ds. Glycosylation analysis methods used were Flu (NP-HPLC analysis of fluorescently labelled, 
released N-glycans), Eth (analysis of released N-glycans by MALDI-TOF-MS after ethyl esterification) and 
GP (analysis of IgG Fc-glycopeptides by LC-MS). N-Acetyl, N-acetylneuraminic acid (NeuAc); N-Glycolyl, 
N-glycolylneuraminic acid (NeuGc).
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markers of inflammation56,57. Low galactosylation of anti-proteinase 3 autoantibodies correlated with inflam-
matory cytokines58. In our experiments, galactosylation correlated with moderately increased ADCC of 
BRAD5lab-b59, glycoengineered IgG160 and hypo-fucosylated anti-D61. Thus, the wide range of galactosylation 
ranging from Rhophylac and IgG1 B mAb-Ds (60–84% galactosylation with <15% G0) to rodent mAb-Ds (15–
57% galactosylation with 18–70% G0) may impact antibody function in various ways.
Sialic acid has been described not to alter ADCC activity of IgG160. Similarly, sialylation of anti-D had little 
or no effect on FcγR binding61 or macrophage phagocytosis of sensitised RBC62. Low sialylation of CHO and 
YB2/0 mAb-Ds (mean 8%) and lack of the α2,6-linkage on CHO mAb-Ds may make them liable to inflammatory 
responses. In addition, non-human Neu5Gc on NS0, HH and G12-yb2/0 mAb-Ds may be immunogenic63,64.
The biological relevance of bisecting GlcNAc is uncertain. Increasing it has been reported to enhance 
FcγRIIIa-mediated ADCC, possibly by affecting fucosylation65,66, but recently, little effect has been found for 
monoclonal anti-D61. Bisection was very high on most B mAb-Ds.
Alpha-galactose (α-Gal epitope: Galα1–3Galβ1-(3)4GlcNAc-R) is synthesised by all mammals except 
humans, apes and Old World monkeys, which produce anti-Gal67, comprising ~1% of human IgG68. Humans also 
have high concentrations of anti-Neu5Gc (usually higher than anti-B (blood group antibody))64. These natural 
Figure 2. Functional activities of anti-D in ADCC assay. (a) The anti-D dependent lysis of red cells by NK cells 
is shown throughout the dilution range of antibody activity. Rhophylac anti-D is compared to mAb-Ds from 
human B cell lines, mouse cell lines, and hamster CHO and rat YB2/0 cell lines. Error bars indicate standard 
deviation (±s.d.). (b) Correlation between ADCC activities of anti-Ds and their glycosylation. Comparison 
is made of the percentage fucosylation, sialylation, galactosylation and bisecting GlcNAc with the percentage 
lysis of the anti-Ds (mAb-Ds and Rhophylac anti-D) shown at 25 ng/ml (left column) and 750 ng/ml (right 
column). The Pearson correlation coefficients for ADCC lysis and fucosylation are shown on the graphs, both 
were significant to p < 0.0001. There was no correlation between ADCC activity and percentage sialylation, 
galactosylation or bisection.
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antibodies may bind mAbs expressing xenogeneic α-Gal and Neu5Gc epitopes, forming immune complexes 
and increasing uptake of target cells to antigen-presenting cells and immunogenicity. All NS0 and HH mAb-Ds 
expressed α-Gal, as reported previously69, and Neu5Gc, also found on mAbs from some murine myelomas70. 
These xenogeneic epitopes may have caused HH mAb-Ds to stimulate anti-D responses, not prevent them. The 
findings by one laboratory of low amounts of α-Gal on some human B mAb-Ds cultured in the absence of animal 
material are unexpected and should be taken with caution as further studies would be needed to substantiate this.
IgG3 anti-D comprises 10% of the anti-D in prophylactic preparations on average71 but is relatively inefficient 
in ADCC compared to IgG1 anti-D as is BRAD3 (IgG3) compared to BRAD5 (IgG1)72. ADCC assays measured 
FcγRIIIa-mediated haemolysis by NK cells although in vivo FcγRIIIa-bearing splenic macrophages phago-cytose 
anti-D opsonised RBC16,17. In vivo, BRAD3clin-b efficiently cleared RBC30,33. In vitro, RBC opsonised with 
BRAD3lab-b had greater mean binding to splenic macrophages in cryostat sections than BRAD5lab-b opsonised 
RBC (58.6 and 25.8 respectively)73. Additionally, using monocyte-derived macrophages, IgG3 mAb-Ds mediated 
higher ADCC than IgG1 mAb-Ds (96% versus 26%)50. This difference in activity may be explained because glyco-
forms of FcγRIIIa vary between NK cells and monocytes74 which may affect affinity to IgG subclasses and bind-
ing of differentially glycosylated IgG. Recognition of afucosylated IgG by FcγRIIIa is in part mediated through 
carbohydrate-carbohydrate interactions involving the N162-glycan found on this receptor47.
The role of cells and FcγRs in RBC clearance is becoming clearer. In vitro, phagocytosis of anti-D opsonised 
RBC by monocytes is mediated by FcγRI, with the extent of phagocytosis proportional to anti-D coverage on 
RBCs50. FcγRI is also present on splenic red pulp macrophages and although at low expression compared to 
FcγRIIIa, it gives a major contribution to phagocytosis75. This may be due to upregulation of surface expression 
of FcγRI after stimulation of FcγRIIIa by binding opsonised RBC or by inflammation75. Thus in vivo, it is likely 
that opsonised RBC are selected and captured by splenic macrophages through FcγRIIIa binding afucosylated 
anti-D followed by FcγRI-mediated internalisation. The spleen has the capacity to phagocytose all the fetal RBC 
in the majority of FMH (volumes over 20 ml fetal RBC are exceptional) without producing spherocytes or free 
haemoglobin. RBC with the highest opsonisation will be removed first, the rate of clearance correlating with the 
amount of RBC-bound anti-D14 (and indirectly to D antigen levels), resulting in progressive slowing of clearance 
of RBC with decreasing anti-D opsonisation. Notably, antigen masking may only occur to a minor extent, as doses 
of anti-D cover only about 8%–20% of D antigen sites on RBC76.
Although the mechanism of anti-D prophylaxis has not been fully elucidated, clinical observations and 
studies performed after the introduction of anti-D Ig suggest it elicits some immunomodulatory processes. (a) 
Prophylactic anti-D appears to have long-term effects. HDFN was found less severe in subsequent pregnancies 
of women who had failures of postnatal prophylaxis compared to infants of multiparae women who had no 
pro-phylaxis77. Antenatal prophylaxis given only during first pregnancies, together with postnatal prophylaxis, 
Ref-
erence Anti-D
% Fucosyl-
ation Comments on clearance
Summary of 
clearance
Dose-response 
effect
Number 
of subjects
30
30
BRAD3clin-b
Fog1-hh
77
93
Very rapid initially then slowed
Very slow, incomplete by 24 h
++++
+
Yes
No
6
31
31
mBRAD3-B + mBRAD5-b
rBRAD3-cho + rBRAD5-cho
85 (mean)
83 (mean)
Rapid initially then slowed
Rapid initially then markedly slowed
+++
++
6
6
28
28
Fog1-yb2/0
Fog1Δnab-yb2/0 (null)
23
46
Extremely rapid, complete by 4 h, some febrile reactions
More than 50% RBC cleared by 4 h
+++++
+++
No 5
6
29
29
R297-yb2/0
Rhophylac 300 34
Extremely rapid, complete by 72 h
Rapid, almost complete by 96 h
+++++
++++
Yes
Yes
6
6
Table 4. Clearance of autologous D-positive RBC precoated with anti-D in D-positive subjects.
Ref-
erence Anti-D
% Fuco-
sylation Comments on clearance
Summary of 
clearance
Number 
of naïve 
subjects
Percentage forming 
anti-D before re-
immunizing IgG IgM
Number of 
responders 
protected
33
33
33
34
35
BRAD3clin-b
BRAD5clin-b
Anti-D Ig
BRAD3clin-b + BRAD5clin-b
BRAD3clin-b + BRAD5clin-b
77
81
80 (mean)
80 (mean)
Mean t50% = 12.7h, dose-response
Mean t50% = 5.9h, dose-response
Mean t50% = 5.0h
Mean t50% = 9.6h
Complete by 72h in 87% (81/93) subjects
++
+++
++++
+++
+++
10
8
8
8
93
0%
0%
0%
0%
1.7%
3 of 3
1 of 1
1 of 1
2 of 2
20 of 22
36
36
AD1-hh + AD3-hh
Anti-D Ig
97 Variable, incomplete
Rapid
+/++
++++
5
4
60%
0%
37
37
37
37
37
G7-hh
G7-hh + G12-hh
G12-hh
G12-hh
Anti-D Ig
90
91
93
93
Moderate
Moderate
Variable, incomplete
Rapid
Rapid
+++
++/+++
+/++
++++
++++
6
3
10
2
2
67% 50%
100% 100%
60% 40%
0% 0%
0% 0%
38
38
MonoRho-cho
Rhophylac 300
93 Slow, very variable t50% = 2-203h no dose-response
Rapid
+/++/+++
++++
31
15
0%
0%
Table 5. Clearance of allogeneic D-positive RBC in D-negative subjects by anti-D and subsequent protection 
against D-immunization (prophylaxis).
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resulted in a 12-fold reduction in cases with D-immunisation in the second pregnancies78. These findings were 
recently confirmed79. It was suggested that the D-immune responses could have been modified by giving anti-D 
after the responses had started but before they had matured77,78. (b) Women with large fetal bleeds (FMH over 
20 ml) who were given appropriate doses of anti-D Ig but had persistence of some circulating fetal RBC 6 days 
after delivery were subsequently found to be protected from D-immunisation, indicating that the immune 
response had been prevented by the sequestered RBC80. (c) IgG anti-Kell (K) injected into K- D- subjects after 
immunisation with K+ D+ RBC gave a 10-fold reduction in anti-D responders, compared to a control group 
not given anti-K. This demonstrated that after rapid clearance of RBC to the spleen, antibody-mediated immune 
suppression is not antigen specific but cell-specific, inhibiting antibody formation to all antigens on the RBC81. 
(d) Besides destruction of the RBC by anti-D Ig, another potential mechanism may be suppression of primed 
antigen-specific B cells by co-cross-linking B cell receptors (binding RBC antigens) and inhibitory FcγRIIb (with 
anti-D Ig) (reviewed in76). Of note, it was reported that the YB2/0 form of a mAb-D, T125, had greater interac-
tions with both FcγRIIIa and FcγRIIb than the CHO form, thus indicating that low fucosylated anti-D would be 
effective in this mechanism of B cell suppression82 as well as in rapid RBC clearance29. (e) Other “non-specific” 
immunomodulatory effects of prophylactic anti-D could be caused by the anti-D or many other alloantibodies in 
the donor pool of immuno-globulins (similar to IVIG) using these mechanisms, such as reductions of anti-Fya in 
a case report83 and of anti-HLA sensitisation in a large survey84. HLA class I antigens (Bg) are expressed on most 
cells including RBC of some normal donors85. (f) Animal models, unfortunately, are generally unsatisfactory for 
understanding anti-D prophylaxis; experiments in immunocompetent mice using xenogeneic cells or glycopro-
teins elicit innate and/or inflammatory reactions, quite unlike allogeneic RBC and anti-D Ig in humans76.
Inflammatory responses must be avoided for RhD prophylaxis. If inflammation accompanies RBC destruc-
tion, splenic macrophages mature to DCs, present antigen to T helper (Th) cells and initiate antibody responses 
to allogeneic proteins18. Understandably, it must not occur with mAb-Ds or immune anti-D may be produced.
Several factors may cause inflammation. (a) Pregnant women have strong systemic immunity with mild 
inflammation10,11 and skewing towards antibody (Th2) responses86 whilst maintaining local (uterine) tolerance to 
the fetus13. They make robust alloantibody responses to small volumes of allogeneic blood. Consequently, most 
protein blood groups on RBC and alloantigens on platelets were discovered by investigating cases of HDFN and 
fetal and neonatal alloimmune thrombocytopenia (FNAIT). (b) Recognition of cells by innate immune recep-
tors may induce phagocytosis accompanied by inflammatory cytokines, promoting antigen presentation; this 
was observed experimentally for RBC immunisation87. (c) Extracellular haemolysis liberates haemoglobin, its 
breakdown products induce systemic inflammatory responses (febrile reactions and cytokine storms) which can 
be dangerous. Haemolysis underlies the pathology of HDFN, delayed haemolytic transfusion reactions, and rare 
reactions of patients with idiopathic thrombocytopenia treated with anti-D88, all occurring when the phagocytic 
capacity of splenic macrophages is saturated and RBC are haemolyzed extracellularly.
Anti-D prophylaxis may be mediated or influenced by cytokines but data are limited. Interleukin (IL)-1Ra, 
an anti-inflammatory cytokine, was detected during monocyte phagocytosis of BRAD3lab-b-opsonised RBC 
in vitro89. Modest increases of tumour necrosis factor-α but not interferon-γ (both pro-inflammatory) were 
observed briefly (at 4 h) after infusion of RBC coated with Rhophylac 300 or R297-yb2/029. After antenatal 
pro-phylaxis, slight reductions of IL-1Ra (pro-inflammatory effect) were observed in plasma of 7 of 10 women 
while modest increases of transforming growth factor-β1 and prostaglandin E2 (immunoregulatory) were 
recorded in 7 and 5 of these women, respectively90. However, no tests to detect fetal cells (FMH) were performed 
so it is possible these changes in 3 of the 17 cytokines tested90 were due to the immunoglobulin component, 
known to have immunomodulatory effects.
Great care must be taken to ensure the safety and efficacy of mAb-Ds at preventing D-immunisation before 
trials are performed in pregnant (and postpartum) women. First, anti-D responses are slow and low titre; half 
of the women immunised during pregnancy produce serologically detectable anti-D by six months post-partum 
and half of them in subsequent pregnancies, presumably after FMH91. Gunson et al. proposed this involves slow 
protracted phagocytosis of fetal RBC as they become effete92. Second, normal adults do not have the enhanced 
humoral immunity of pregnant women; anti-D developed in 50% of subjects only after 2–5 injections of 
D-positive RBC and rapid clearance of these RBC often occurred before anti-D was detected serologically93. 
Therefore, in the early clinical trials of anti-D, subjects were re-immunised with D-positive RBC several times 
between 6 and 12 months33–35,94. Primary and secondary anti-D responses were detectable 2–4 months or 1–4 
weeks after re-immunisation, respectively. This determines which subjects were (a) D-immunised by the first 
injection of RBC (failure of prophylaxis), (b) D-immunised after RBC challenge (protection by prophylaxis) and 
(c) non-responders who never make anti-D (non-informative).
Thus both appropriate clinical testing and anti-D glycosylation are required for success with prophylactic 
mAb-Ds. The previously published clinical trial data of the anti-Ds in this study can be summarised. Anti-D 
Ig: high ADCC, very rapid RBC clearance, prevented D-immunisation. B mAb-Ds: (BRAD3, BRAD5) medium 
ADCC, fast clearance, prevented D-immunisation in 93% subjects, insufficient dose. HH mAb-Ds: (Fog1, AD1, 
G7, G12) low ADCC, variable and slow clearance, stimulated D-immunisation. CHO mAb-Ds: (BRAD3, BRAD5, 
MonoRho) low ADCC, slow and variable clearance, MonoRho may have prevented D-immunisation but this is 
not proven. YB2/0 mAb-Ds: (Fog1, Fog1Δnab, R297) very high ADCC, extremely rapid clearance.
Unfortunately, after much work over three decades, none of the mAb-Ds in this study and also Sym001-cho 
(Rozrolimupab)95 are still in clinical development for prophylaxis against HDFN although the results of preven-
tion of D-immunisation in a phase II/III trial of Roledumab-yb2/0 (R297 with low fucosyl transferase)96,97 are 
awaited with great interest.
Prophylaxis against FNAIT has been proposed and anti-HPA-1a immunoglobulin is being pre-
pared from women immunised by pregnancy for trials98. Because anti-HPA-1a is rarely produced after 
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platelet transfusion99,100, donors could not be immunised for anti-HPA-1a immunoglobulin, thus monoclonal 
anti-HPA-1a would be needed for prophylaxis101.
This study has shown that the biological activity of mAb-Ds is defined by their producer cell lines. Our results 
indicate that glycosylation is likely a key determinant of clinical effectiveness. The optimal glycosylation for 
prophylactic mAb-Ds (and monoclonal anti-HPA-1a) might be different from that of highly cytotoxic mono-
clonal antibodies for cancer therapy102, because haemolysis and inflammation must be avoided. Therefore, to 
copy and replace anti-D Ig and to prevent possible adverse effects, galactosylation should be over 60% with 
G2 > G1 > G0 to enhance functional activity. However, lower fucosylation (under 60%) than in most prophylactic 
anti-Ds25 would promote efficient FcγRIIIa interactions and rapid RBC clearance at low mAb-D concentrations. 
From the available data, these limits may be the best current estimate for reliable, potent mAb-Ds. Of note, abun-
dant supplies of safe, effective and affordable mAb-D are urgently needed to reduce the global burden of HDFN.
Materials and Methods
igG antibodies. mAb-Ds were produced from human EBV-transformed B-lymphoblastoid cell lines 
(B), mouse myeloma cell lines (NS0 or mouse/human heterohybridomas (HH) formed by fusion of B and 
P3X63Ag8.653 cell lines), Chinese hamster ovary (CHO) cell lines and rat myeloma YB2/0 or rat/human het-
erohybridoma cell lines. All mAb-Ds were IgG1 except BRAD3 (IgG3). The following individuals submitted 
antibodies for glycosylation analysis: Sylvia Miescher, (Rhophylac 300 (300 µg, 1500 IU, 2 ml) anti-D Ig (Quality 
Control Grade, Lot 02905-00092) and MonoRho-cho); Rosey Mushens, (BRAD3lab-b, BRAD5lab-b, JAC10-b, 
AB5-b, Fog1-hh); Joan Dalton, (BRAD3clin-b, mBRAD3-b, rBRAD3-cho, BRAD5clin-b, mBRAD5-b, rBRAD5-
cho); Natalia Olovnikova (G7-b, G7-hh, G12-b, G12-hh, G12-yb2/0 (rat/human), G108-b); Christof de Romeuf, 
(AD1-hh, R297-yb2/0); Kathryn Armour (Fog1-ns0, Fog1-yb2/0 and Fog1Δnab-yb2/032). BRAD3lab-b and 
BRAD5lab-b were prepared from low cell density flask cultures for experimental use and BRAD3clin-b and 
BRAD5clin-b were produced for clinical testing33 in high cell density hollow fibre bioreactors; mBRAD3-b, 
mBRAD5-b, rBRAD3-cho and rBRAD5-cho were subsequently also produced from hollow fibre bioreactors31. 
IVIG (Hepatect CP 50 IU/ml) was kindly provided by P. Griffiths from Biotest (UK) Ltd, Birmingham, UK.
Purification and quantification of IgG anti-D. Anti-D was affinity purified from Rhophylac 300 anti-D 
Ig44. IgGs from this RBC eluate and from culture supernatants of mAb-Ds were purified using Protein G and IgG 
concentrations determined by ELISA. Only IgG1 was detected in anti-D purified from Rhophylac 300 (at 10 μg/mL) 
by haemagglutination with anti-IgG subclass mAbs44. The anti-D fraction termed Rhophylac was used in this study.
Glycosylation analysis 1: N-glycan analysis in NIBRT GlycoScience Group, Dublin (Flu). 
Antibodies were reduced, alkylated and N-glycans were released from IgG heavy chain from SDS-PAGE gel bands 
by digestion with N-glycosidase F (PNGase F, Prozyme, San Leandro, CA) as described by Royle et al.103. Briefly, 
gels were washed and N-glycans were released by PNGase F. Released N-glycans were fluorescently labelled 
with 2-aminobenzamide (2-AB) by reductive amination using a LudgerTagTM 2-AB labelling kit (Ludger Ltd., 
Abingdon, UK) and excess of 2-AB was removed by paper chromatography103.
Labelled glycans were analysed by 3 hours normal phase high-performance liquid chromatography (NP-HPLC) 
using a TSK-Gel Amide-80 4.6 × 250 mm column (Anachem, Luton, UK) on a 2695 Alliance separations mod-
ule (Waters, Milford, MA) equipped with a Waters temperature control module and a Waters 2475 fluorescence 
detector. Solvent A was 50 mM formic acid adjusted to pH 4.4 with ammonia solution. Solvent B was acetonitrile. 
Gradient conditions were a linear gradient of 20–58% A, over 152 min at a flow rate of 0.4 mL/min. Samples were 
injected in 80% acetonitrile103. Fluorescence was measured at 420 nm with excitation at 330 nm. The system was 
calibrated using an external standard of hydrolysed and 2AB-labeled glucose oligomers to create a dextran ladder, 
as described previously103. NP-HPLC chromatograms generated from the samples are in Supplementary Fig. S1.
For exoglycosidase digestion of 2-AB labelled N-glycans, enzymes were supplied by Prozyme. The 2AB-labelled 
glycans were digested in a volume of 10 μL for 18 h at 37 °C in 50 mM sodium acetate buffer, pH 5.5 (except in the case 
of jack bean α-mannosidase (JBM) where the buffer was 100 mM sodium acetate, 2 mM Zn2+, pH 5.0), using arrays 
of the following enzymes: Arthrobacter ureafaciens sialidase (ABS, EC 3.2.1.18), 0.5 U/mL; Streptococcus pneumoniae 
sialidase (NAN1, EC 3.2.1.18), 1 U/mL; coffee bean alpha galactosidase (CBG, EC 3.2.1.22), 25 U/mL; bovine testes 
β-galactosidase (BTG, EC 3.2.1.23), 1 U/mL; bovine kidney alpha-fucosidase (BKF, EC 3.2.1.51), 1 U/mL and JBM (EC 
3.2.1.24), 60 U/mL. After incubation, enzymes were removed by filtration through 10 kDa protein-binding EZ filters 
(Millipore Corporation)103. N-glycans were assigned using exoglycosidase digestions (Supplementary Table S2) and 
Glycobase and features outlined in Tables 1–3 were calculated based on these assignments (Supplementary Table S2).
Glycosylation analysis 2: N-glycan analysis at Leiden University Medical Center. IgG Total 
N-glycosylation analysis (Eth). After protein denaturation, N-glycans were released with 1 mU recombinant 
peptide-N-glycosidase F (PNGase F; Roche Diagnostics, Mannheim, Germany) at 37 °C overnight as described 
previously104,105. The selective ethyl-esterification of 2,6-linked sialic acids and lactonization of 2,3-linked sialic 
acid was performed on the released N-glycans106, followed by glycan purification by HILIC-SPE using cotton as 
stationary phase107 and glycan elution with 10 µl of water. For MALDI-TOF-MS analysis, samples were spotted 
on an AnchorChip MALDI target (Bruker Daltonics, Bremen, Germany) together with sodiated (1 mM NaOH) 
Super-DHB (Sigma-Aldrich) matrix. All analyses were performed on an UltraFlextreme MALDI-TOF/TOF-MS 
equipped with a Smartbeam II laser (FlexControl 3.4 Build 119, Bruker Daltonics). The MS was operated in reflec-
tron positive (RP) ion mode, calibrated on the known masses of a peptide calibration standard (Bruker Daltonics). 
For sample measurements 10000 laser shots were accumulated at a laser frequency of 1000 Hz, using a complete 
sample random walk with 200 shots per raster spot. Tandem mass spectrometry (MALDI-TOF/TOF-MS/MS) 
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was performed on mostly sialylated variants of IgG glycans via laser-induced dissociation, and compositions as 
well as structural features of N-glycans were confirmed on the basis of the observed fragment ions (not shown).
Spectra were exported as text and subjected to recalibration and data extraction using an in-house devel-
oped Python script. Glycan peaks were detected and extracted using a signal/noise cut-off of 3. Total glycan 
intensity per spectrum was normalised to 100%, and derived traits were calculated based on the compositional 
features (Supplementary Tables S3 and S4) (hexose = H; N-acetylhexosamine = N; fucose = F; α2,6-linked 
N-acetylneuraminic acid = E; α2,3-linked N-acetylneuraminic acid = L; α2,6-linked N-glycolylneuraminic 
acid = Ge; α2,3-linked N-glycolylneuraminic acid = Gl).
Glycosylation analysis 3: IgG Fc glycopeptide analysis (N-glycosylation) at Leiden 
University Medical Center (GP). IgG was enzymatically digested with trypsin and analysed by 
reverse phase-nanoLC-MS. Electrospray ionisation was achieved with a CaptiveSpray nanoBooster (Bruker 
Daltonics) using acetonitrile-enriched nitrogen gas to enhance sensitivity. Glycopeptides were detected using 
a quadrupole-time-of-flight (TOF) mass spectrometer (MS) (maXis impact HD ultra-high resolution QTOF; 
Bruker Daltonics)108. Double and triple charged tryptic Fc glycopeptide signals were integrated and normalised 
to the subclass-specific total glycopeptide intensity. Quality of mass spectra was evaluated based on intensities of 
total IgG1 glycoforms. Glycosylation traits were calculated as detailed in Supplementary Table S3.
Analysis of mAb-D glycosylation in small scale earlier studies. Methods used for other studies 
reported in Supplementary Table S1 were MALDI-TOF-MS analysis of IgG1 Fc-glycopeptides25, analysis by 
HVE-AEC, gel filtration chromatography and Concanavalin A binding of oligosaccharides released by hydraz-
inolysis109, quantitation of % G0 by binding of GlcNAc-specific mAb GN759, chromatographic separation of 
fluorescently labelled neutral oligosaccharides49, enzymatically released glycans analysed by HPCE-LIF82 and 
FAB-MS and MALDI-MS of permethylated N-glycans (Carbohydrate structure of rBRAD-3 and rBRAD-5; Joan 
Dalton, BioProducts Laboratory, UK, email, September 26, 2007; permission to publish subsequently given).
ADcc assay. Peripheral blood mononuclear cells (PBMC) depleted of adherent monocytes were incubated in 
triplicate for 16 h at 37 °C with papainized 51Cr-labelled group OR1R2 RBC (15:1 ratio) and anti-D in RPMI1640 
containing 3% AB serum (to block FcγRI on residual monocytes)50 and 7% fetal calf serum; after centrifugation, 
radioactivity was determined in aliquots of supernatant72. The percent specific lysis (% haemo-lysis) was calculated 
as: % specific lysis = 100 × (experimental release – spontaneous release)/(maximum release – spontaneous release). 
To confirm FcγR utilisation, lysis by IgG1 anti-D was blocked by anti-FcγRIII (3G8) but not by anti-FcγRII (IV.3)50.
Analysis of data from previous clinical trials of RBC clearance and prevention of D-immunization. 
The efficacy of prophylactic anti-D Ig depends on removal of fetal RBC from the circulation by 72 hours110. 
Clinically, tests for FMH are performed to determine whether fetal D-positive RBC have been cleared by this time111. 
For initial clinical trials, pre-menopausal women are not enrolled because they might become D-immunised which 
could lead to HDFN in subsequent pregnancies. Early studies showed that if anti-D prevented D-immunisation in 
men, it would be suitable for prophylaxis in women. Using healthy male volunteers, eight mAb-Ds had been tested 
in four autologous RBC clearance studies and seven mAb-Ds in five allogeneic RBC clearance studies. All the trial 
protocols varied; details of methods, ethics approval and informed consent are given in the original papers cited in 
Tables 4 and 5. Autologous RBC clearance measured the extent of radioactivity remaining in blood of D-positive 
subjects after injection of their ex vivo 51Cr labelled RBC coated with anti-D. Study periods were between 1 h and 
6 days after injection. Allogeneic studies measured clearance of D-positive RBC (labelled with 51Cr or detected by 
flow cytometry) injected into D-negative recipients before (simulating postnatal prophylaxis) or after (equivalent 
to antenatal prophylaxis) anti-D administration, with blood samples taken up to 7 days. To assess whether mAb-D 
could prevent D-immunisation, these subjects were then tested regularly (every 2 or 4 weeks) for 6 months to detect 
anti-D responses (indicating failure of prophylaxis). In studies of B mAb-Ds, subjects were then re-immunised with 
D-positive RBC at 6 and 9 months and tested regularly up to a year to determine which were responders to these 
unprotected immunisations who had been prevented from making anti-D after the first RBC injection by mAb-Ds.
Data availability
All data generated or analysed during this study are included in this published article and its Supplementary 
Information files. Not all mAb-Ds (antibodies or cell lines) may be available due to being produced many years 
ago in laboratories that have since ceased working on them or closed down.
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